asieris

Asieris Pharmaceuticals is a China-based biopharmaceutical company developing innovative therapies in genitourinary tumors and women's health. Its focus areas span urologic oncology (bladder cancer diagnosis and treatment), women's health, and breast and gynecologic oncology, with marquee assets Vesique (APL-1202) for bladder cancer and Cevira (APL-1702), a non-invasive photodynamic therapy for cervical precancerous lesions. The company runs three proprietary R&D platforms (TIMN, TAIDD, DDC). It was surfaced as a portfolio company of Qiming and added to the API Evangelist network; as a biopharma company it publishes no public developer API surface.

asieris is profiled on the APIs.io network. Tagged areas include Company, Pharmaceuticals, Biotechnology, Healthcare, and Oncology.

asieris’ developer surface includes support, engineering blog, and 6 more developer resources.

🌐 Visit website 📡 Source on GitHub

10.5/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0

0 APIs

CompanyPharmaceuticalsBiotechnologyHealthcareOncologyWomen's HealthLife Sciences

Kin Score

Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0

Composite quality — 10.5/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 1.2 / 17

Access Clarity 3.6 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 2.6 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/asieris: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 4

The organization behind the API

Website

Website

About

Blog

Source (apis.yml)

aid: asieris
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/asieris.png
name: asieris
description: Asieris Pharmaceuticals is a China-based biopharmaceutical company developing innovative therapies in genitourinary
  tumors and women's health. Its focus areas span urologic oncology (bladder cancer diagnosis and treatment), women's health,
  and breast and gynecologic oncology, with marquee assets Vesique (APL-1202) for bladder cancer and Cevira (APL-1702), a
  non-invasive photodynamic therapy for cervical precancerous lesions. The company runs three proprietary R&D platforms (TIMN,
  TAIDD, DDC). It was surfaced as a portfolio company of Qiming and added to the API Evangelist network; as a biopharma company
  it publishes no public developer API surface.
url: https://raw.githubusercontent.com/api-evangelist/asieris/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- qiming
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Pharmaceuticals
- Biotechnology
- Healthcare
- Oncology
- Women's Health
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/asieris-domain-security.yml
- type: Website
  url: https://asieris.cn
- type: Website
  name: Asieris (English)
  url: https://asieris.com/
- type: About
  url: https://asieris.com/about/
- type: Support
  name: Contact
  url: https://asieris.com/contact/
- type: Blog
  name: News
  url: https://asieris.com/news/
- type: PrivacyPolicy
  url: https://asieris.com/privacy-policy/
- type: TermsOfService
  url: https://asieris.com/termsuse/
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence